Ventyx Invest Advisor

Ventyx Biosciences Commences Phase 2a Trial for VTX3232 in Early Parkinson's Disease Patients Sep 6, 2024

Ventyx Biosciences Announces Participation in the 35th Annual Piper Sandler Healthcare Conference Nov 22, 2023